Approval Provides U.S. Veterans and Other U.S. Government Agency Employees Access to the Only Portable Neurostimulation Therapy with the Potential to Generate Neuroplasticity
NEWTOWN, Pa. May 20, 2024 - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a leading neurotech company focused on developing innovative therapeutic neuromodulation solutions, has announced that its flagship product, the Portable Neuromodulation Stimulator (PoNS®) device, has been approved for inclusion on Lovell Government Services’ Veterans Affairs (VA) Federal Supply Schedule (FSS) and the General Services Administration (GSA) Advantage contracts.
This critical approval opens the door for U.S. veterans and other government employees who suffer from impairments in gait and balance due to multiple sclerosis (MS) to access PoNS, the only portable neurostimulation therapy with the potential to generate neuroplasticity. Neuroplasticity refers to the brain’s ability to reorganize itself by forming new neural connections, which is crucial for restoring function impaired by injury or disease.
A Landmark Step for Veteran Healthcare
The inclusion of the PoNS device on these federal procurement schedules is a landmark step in ensuring that U.S. veterans receive cutting-edge medical care. Multiple sclerosis, a chronic and often disabling disease, affects the central nervous system, causing a wide range of symptoms including difficulties with balance and gait. The availability of PoNS is expected to have a significant positive impact on the quality of life of veterans living with MS.
We are thrilled to achieve this milestone approval, said a spokesperson for Helius Medical Technologies. Our partnership with Lovell Government Services and the inclusion of PoNS on the VA FSS and GSA Advantage contracts highlight our commitment to providing veterans with advanced medical technologies. We believe PoNS has the potential to transform the lives of veterans who struggle with the debilitating effects of multiple sclerosis.
How PoNS Works
The PoNS device is a groundbreaking technology designed to stimulate the cranial nerves non-invasively via the tongue, which in turn sends signals to the brain to promote the development of new neural pathways. This type of neuromodulation therapy has shown promise in improving motor functions and balance in patients, making it an invaluable tool for those grappling with MS.
PoNS therapy is integrated into a comprehensive program that includes physical therapy designed to enhance the overall benefits of neurostimulation. The therapy is tailored to the specific needs of each patient and is supervised by healthcare professionals to ensure optimal outcomes.
Accessibility and Affordability
With the PoNS device now accessible through VA and GSA contracts, a broader demographic of veterans and government employees can benefit from this advanced neurostimulation therapy. The FSS and GSA Advantage programs streamline procurement processes, making it easier for institutions to acquire innovative medical technologies and ensuring that those who serve or have served the nation are not left behind in receiving cutting-edge medical care.
Expert Endorsements and Future Prospects
The PoNS device has garnered attention and support from key opinion leaders in the medical community. Its inclusion on federal schedules is expected to pave the way for further integrations into other healthcare systems and institutions.
Moreover, this approval not only enhances the device’s credibility but also affirms Helius Medical Technologies’ standing as a pioneer in the neurotech field. The company aims to continue its research and development efforts to expand the therapeutic applications of PoNS and improve the lives of those affected by various neurological conditions.
Conclusion
The approval of Helius Medical Technologies’ PoNS device for inclusion on the VA FSS and GSA Advantage contracts represents a monumental advancement in the treatment options available to U.S. veterans and government employees suffering from gait and balance impairments due to multiple sclerosis. By facilitating access to this transformative technology, the company reinforces its commitment to enhancing the quality of life for individuals affected by MS and pushing the boundaries of neurostimulation therapy.
Comments